

CLINICAL LABORATORIES Q2 2024 VALUATION UPDATE



Introduction

We are pleased to share our Clinical Laboratories Industry Multiples Valuation Update for Q2 2024.

At Seale & Associates, we are committed to providing process-driven solutions designed to optimize value and achieve our client's strategic objectives in a range of transactions, including Mergers, Acquisitions, Divestitures and Carve-Outs, Business Sales, Recapitalizations, and Joint Ventures, among other corporate finance and strategy consulting services.

Over the course of 25+ years, we have successfully served clients all over the world, and we are delighted to continue providing investment banking advisory services to our clients who are looking to grow through acquisitions or optimize their portfolios through strategic divestitures.

Seale has extensive experience advising leading multinational companies, private equity firms, and family-owned businesses across a wide range of industries.

CLINICAL LABORATORIES Q2 2024



James A. Seale | President jseale@sealeassociates.com



Brett M. Carmel | Senior Managing Director bcarmel@sealeassociates.com



Robert Whitney | Managing Director rwhitney@sealeassociates.com



Sergio Garcia del Bosque | Managing Director sgarcia@sealeassociates.com



Carlos Hernández Goudet | Managing Director chernandez@sealeassociates.com





Alejandro Montemayor | Vice President amontemayor@sealeassociates.com

Armando Rios | Vice President arios@sealeassociates.com

2




 \bigcirc

Clinical Labs Industry Overview, M&A Trends and Market Intelligence

Key M&A Trends Shaping the Industry

- The global clinical laboratory market size is estimated to grow from US\$274.2 billion in 2024 and is expected to reach US\$468.1 billion by 2032, growing at a CAGR of 6.9%
- There is a significant interest from private equity firms in acquiring clinical laboratory services. These investments are motivated by the stable cash flows and growth potential of these services, particularly in the wake of increasing demand for diagnostic tests and personalized medicine
- The independent laboratory segment is experiencing huge consolidation as players focus on strategic partnerships and collaborations, which will drive the market's growth
- Large organizations, including those with clinical laboratory services, are actively **divesting non-core assets**. This strategy is intended to **reduce R&D expenses** and **generate cash** to fund new **investments** that align more closely with their core competencies
- Companies are increasingly pursuing M&A opportunities to integrate artificial intelligence (AI) and digital capabilities. These technologies are sought to enhance diagnostic accuracy and operational efficiency, positioning firms for stronger growth and improved patient outcomes in 2024



Clinical Laboratories Industry M&A Deal Size and Volume

■ Deal Size (US\$M) → Deal Count

Clinical Laboratories Market Trends

Adoption of next-generation sequencing (NGS), digital pathology, and artificial intelligence (AI) is **enhancing diagnostic accuracy** and **efficiency**

Increased automation to improve **efficiency**, **reduce turnaround times**, and **minimize errors**

Emphasis on **affordable diagnostic solutions** through centralized networks and advanced technologies

Enhanced collaboration between **public health institutions** and **private labs** to improve access to advanced diagnostic services

Growth in emerging markets with **investments** in **healthcare infrastructure** and **increased accessibility** to diagnostic services

F

S

Contraction of the second

(Ta)

)	2	2	0	2	4
•	_	_	<u> </u>	_	



Clinical Laboratories Industry Global Comparable Public Companies

		Country	Market Cap. US\$M	Enterprise Value US\$M	Revenue US\$M	EBITDA	Annual Average EV/EBITDA		Second Quart Jun. 30, 202	
Company		Country				Margin	2022	2023	EV/ EBITDA	E Revo
Alliança Saúde e Participações S.A.	alliar médicos à frente sistema de diagnósticos de saúde	BRA	\$221	\$410	\$214	8.2%	19.5x	35.4x	23.4x	1.
Capitol Health Limited	CAPITOLHEALT	AUS	\$224	\$308	\$157	16.3%	11.2x	10.4x	12.0x	2.
Dian Diagnostics Group Co.,Ltd.	www 迪安诊断 DIAN DIAGNOSTICS	CHN	\$1,023	\$1,585	\$1,759	10.8%	7.0x	6.2x	8.3x	0
Fleury S.A.	fleury medicina e saúde	BRA	\$1,477	\$2,080	\$1,343	23.8%	7.3x	8.5x	6.5x	1.
Healius Limited	III healius	AUS	\$727	\$1,747	\$1,165	19.2%	5.4x	7.5x	7.8x	1.
Integral Diagnostics Limited		AUS	\$417	\$646	\$313	18.6%	13.5x	12.6x	11.1x	2
Krsnaa Diagnostics Limited	Krsnad DIAGNOSTICS LET'S DO GOOD	IND	\$235	\$248	\$78	22.2%	12.1x	13.6x	14.3x	3.
Med Life S.A.	MedLife	ROM	\$681	\$1,009	\$530	12.8%	12.1x	13.9x	14.9x	1.
Excluded from mean and median						Mean Median	9.8x 11.6x	10.4x 11.5x	10.0x 11.6x	1. 1.








Clinical Laboratories Industry Global Comparable Public Companies

Company		Country	Market Cap. US\$M	Enterprise Value US\$M	Revenue US\$M	EBITDA Margin	Annual Average EV/EBITDA		Second Quart Jun. 30, 202	
Company		Country					2022	2023	EV/ EBITDA	E Rev
Eurofins Scientific SE	🛟 eurofins	LUX	\$9,619	\$12,577	\$7,204	19.9%	9.7x	9.8x	8.8x	٦.
Labcorp Holdings Inc.	C labcorp	USA	\$17,155	\$23,118	\$12,488	15.2%	7.0x	9.3x	12.2x	٦.
Medicover AB (publ)	MEDICOVER	SWE	\$2,697	\$3,813	\$2,047	12.8%	12.8x	13.9x	14.5x	1.
Quest Diagnostics Incorporated	Quest Diagnostics	USA	\$15,206	\$20,198	\$9,346	23.1%	6.6x	9.0x	9.4x	2.
RadNet, Inc.	RadNet	USA	\$4,353	\$5,554	\$1,714	20.9%	8.1x	10.6x	15.5x	3.
Sonic Healthcare Limited	SONIC HEALTHCARE	AUS	\$8,430	\$10,805	\$5,983	16.5%	7.0x	9.0x	11.0x	٦.
SYNLAB AG	SYNLAB	DEU	\$2,637	\$3,969	\$2,802	16.9%	4.7x	7.3x	8.4x	1.
Excluded from mean and median						Mean	7.2x	9.1x	9.9x	٦.
						Median	7.0x	9.3x	11.0x	٦.







Clinical Laboratories – Global Transactions

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA Re
Jun-24*	medinova diagnostic services enabling diagnosis ensuring health the of Vigos Depress Correr – Indended	IND	Provides diagnostic imaging, pathology, and specialized lab services	VIJAYA [°] DIAGNOSTIC CENTRE	-	37.9%	\$1.6	13.8x
Jun-24	LABORATOIRE DE BIOLOGIE MÉDICALE	FRA	Provides clinical pathology testing and diagnostics	iNOVIE	-	100.0%	-	-
Jun-24	Medistica Gynaecology + Fertility	POL	Provides gynecology, fertility treatments, and assisted reproductive technologies	OW Proton	Medistica®	>50.0%	-	-
Jun-24*	CAPITOLHEALTH	AUS	Provides diagnostic imaging services		-	100.0%	\$313.7	10.2x
May-24	Desert Tox, LLC	USA	Provides laboratory drug testing services	Premier BIOTECH	-	100.0%	-	-
May-24	WUSIC	USA	Provides 3D mammography, ultrasound, and bone density imaging services	SOLIS Mammography	-	100.0%	-	-
May-24	Associate Pathologists of Joliet, Ltd.	USA	Provides pathology services, including diagnostic testing and clinical analysis	VERSANT	-	100.0%	-	-
Apr-24	Dallas IVF	USA	Provides fertility treatments	FERTILITY	-	100.0%	-	-

*Announced transactions pending approval and other customary closing conditions










Private Equity Transactions



Notes:

- this blind approach, the data submitted is less likely to be biased or manipulated.

• Data obtained via GF Data, a subscription-based information platform, offering detailed information and metrics about the transactions of Private Equity funds in the U.S. • The data is provided under a blind confidential format. Users of the data are unable to identify the exact company and transaction corresponding to the transaction details. Given





Sign up for M&A insights

We deliver sector-specific intelligence designed specifically for industry leaders, private equity firms, and their advisors. Our industry reports and featured articles deliver real-time access to key industry data, including:



Emerging industry trends

Quarterly reports covering 30+ industries Monthly reports for the U.S., Mexico, and Colombia

Transaction analysis and market trends

Valuable insights for industry leaders

Receive email updates with our proprietary data, reports, and insights as they are published for the industries that matter to you the most

SUBSCRIBE







 \bigcirc

Global M&A Representative Engagements









JAMES A. SEALE

President and Founder | Washington, DC



32+ years of global M&A experience, Attorney, CPA Arthur Andersen, and Professor of Global Investment Banking at George Washington University University of Virginia - JD University of Kentucky - BS in Accounting



SERGIO GARCIA DEL BOSQUE

Managing Director | Mexico City, Mexico



+52 (55) 8000-7463

16+ years of global M&A experience **IPADE - MBA** Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering



CARLOS HERNANDEZ GOUDET

Managing Director | San Luis Potosi, Mexico



14+ years of global M&A experience Columbia University - MBA Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering








Please contact us if you would like further information about M&A trends and/or specific transaction multiples for your industry. © Seale & Associates

CLINICAL LABORATORIES Q2 2024



BRETT M. CARMEL

Senior Managing Director and Co-founder | Miami, FL

+1 (703) 294-6530

25+ years of global M&A experience and Professor of M&A at Johns Hopkins University

The George Washington University - MBA International Business and MA - International Affairs

University of Florida - BA in Political Science with High Honors




ROBERT E. WHITNEY

Managing Director | Washington, DC

+1 (703) 801-8939

19+ years of global M&A experience, CPA Deloitte & Touche, Corporate Audit and Assurance Services

University of Richmond - BS Business Administration in Accounting



FELIPE BUENO

Senior Director | Monterrey, Mexico



+52 (84) 4432-4444

32+ years with Grupo Industrial Saltillo with experience as Director, Corp. Dev. and extensive global commercial experience Instituto Tecnologico y de Estudios Superiores de Monterrey MBA and BS in Industrial Engineering

Monterrey







Creative Solutions. Trusted Advice.

For over 25 years, Seale & Associates has served leading public and private companies from around the world and operating in a broad range of industries with a high level of quality, integrity and independence while presenting innovative ideas and trusted solutions to address their most complex dealings.



YEARS OF EXPERIENCE \$50B+

TRANSACTIONS GLOBALLY

Trusted Advisor to Leading Companies Worldwide

We have worked repeatedly with many of the most well-



CLINICAL LABORATORIES Q2 2024

SERVICES AND SOLUTIONS

Mergers & Acquisitions Due Diligence / Support Divestitures Expert Witness Testimony Joint Ventures / Alliances **Corporate Finance Advisory** Recapitalizations Strategy Consulting





 \bigcirc

Seale & Associates Creative Solutions. Trusted Advice.

